REGULATED PRESS RELEASE published on 04/18/2024 at 07:00, 7 months 6 days ago Biophytis annonce la création d'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l'obésité Biophytis annonce la création d'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l'obésité, avec dépôt d'IND auprès de la FDA dans les prochaines semaines FDA Biophytis Conseil Scientifique Étude Clinique Obésité
REGULATED PRESS RELEASE published on 04/18/2024 at 07:00, 7 months 6 days ago Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity Biophytis forms new Scientific Advisory Board for phase 2 OBA clinical study in obesity, including Professor Dennis Villareal and Professor Francisco Guarner. IND filing with FDA imminent Biophytis Scientific Advisory Board Obesity Phase 2 OBA Clinical Study IND Filing
BRIEF published on 04/15/2024 at 07:05, 7 months 9 days ago Biophytis Enhances Intellectual Property in Obesity Treatment with New Patent Application Biophytis Pharmaceuticals Patent Application BIO101 Obesity
BRIEF published on 04/15/2024 at 07:05, 7 months 9 days ago Biophytis annonce une nouvelle demande de brevet dans le domaine de l'obésité Biophytis Propriété Intellectuelle BIO101 Obésité Demande De Brevet
REGULATED PRESS RELEASE published on 04/15/2024 at 07:00, 7 months 9 days ago Biophytis files a patent application and strengthens its intellectual property in obesity Biophytis files a patent application to strengthen its intellectual property in obesity. The new patent extends BIO101's exclusivity period in treating obesity, positioning Biophytis in a fast-growing market Biophytis Intellectual Property Clinical Trial Patent Application Obesity
REGULATED PRESS RELEASE published on 04/15/2024 at 07:00, 7 months 9 days ago Biophytis dépose une demande de brevet et renforce sa propriété intellectuelle dans l’obésité Biophytis renforce sa propriété intellectuelle en déposant une demande de brevet pour le traitement de l’obésité, soulignant le potentiel de BIO101 (20-hydroxyecdysone) sur un marché en pleine croissance Biophytis Propriété Intellectuelle Traitement Brevet Obésité
BRIEF published on 04/08/2024 at 23:17, 7 months 15 days ago Biophytis annonce ses résultats financiers pour 2023 et actualise sur ses activités Biophytis Résultats Financiers 2023 Programmes Cliniques BIO101 Sarcopénie Et COVID-19
BRIEF published on 04/08/2024 at 23:17, 7 months 15 days ago Biophytis Reports 2023 Financial Results and Business Updates Biophytis Financial Results 2023 Sarcopenia BIO101 COVID-19 Treatment
BRIEF published on 04/08/2024 at 23:15, 7 months 15 days ago Biophytis Initiates Phase 2 Clinical Study for Obesity Treatment with BIO101 Biophytis Obesity Treatment BIO101 GLP-1 Receptor Agonists OBA Phase 2 Study
BRIEF published on 04/08/2024 at 23:15, 7 months 15 days ago Biophytis annonce le lancement de l'étude clinique de phase 2 OBA pour le traitement de l'obésité Biophytis Santé Étude Clinique BIO101 Obésité
Published on 11/22/2024 at 23:55, 1 day 7 hours ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 1 day 8 hours ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 1 day 8 hours ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 1 day 9 hours ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 1 day 13 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 1 day 13 hours ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 1 day 14 hours ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:15, 1 day 15 hours ago NRJ GROUP - Le Conseil d'Etat rejette le recours de NRJ 12 et NRJ GROUP
Published on 11/21/2024 at 06:58, 3 days ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio